Plandaí Biotechnology, Inc.
PLPL · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 18.35 | -0.01 | 0.00 | -0.00 |
| FCF Yield | 0.00% | 116.14% | 18.49% | 72.94% |
| EV / EBITDA | 0.00 | 0.38 | -0.16 | 1.35 |
| Quality | ||||
| ROIC | 0.00% | -3,811.00% | 180.94% | 1.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.98 | -0.03 | 1.02 | -1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 2,702.26% | -91.99% | 104,444.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -0.00 | 0.02 |
| Interest Coverage | 0.00 | -841.28 | -25.18 | -0.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |